302 related articles for article (PubMed ID: 12558570)
1. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid.
Coupez R; Nicolas JM; Browne TR
Epilepsia; 2003 Feb; 44(2):171-8. PubMed ID: 12558570
[TBL] [Abstract][Full Text] [Related]
2. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy.
Otoul C; De Smedt H; Stockis A
Epilepsia; 2007 Nov; 48(11):2111-5. PubMed ID: 17651416
[TBL] [Abstract][Full Text] [Related]
3. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy.
Trinka E; Marson AG; Van Paesschen W; Kälviäinen R; Marovac J; Duncan B; Buyle S; Hallström Y; Hon P; Muscas GC; Newton M; Meencke HJ; Smith PE; Pohlmann-Eden B;
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1138-47. PubMed ID: 22933814
[TBL] [Abstract][Full Text] [Related]
4. Resting-state fMRI revealed different brain activities responding to valproic acid and levetiracetam in benign epilepsy with central-temporal spikes.
Zhang Q; Yang F; Hu Z; Zhang Z; Xu Q; Dante M; Wu H; Li Z; Li Q; Li K; Lu G
Eur Radiol; 2017 May; 27(5):2137-2145. PubMed ID: 27553940
[TBL] [Abstract][Full Text] [Related]
5. [Which factors have an impact on levetiracetam serum concentrations? An analysis in 163 patients with epilepsy].
Bauer J; Pfeiffer C; Burr W
Nervenarzt; 2010 Apr; 81(4):391-5. PubMed ID: 20111854
[TBL] [Abstract][Full Text] [Related]
6. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
7. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate.
Fountain NB; Conry JA; Rodríguez-Leyva I; Gutierrez-Moctezuma J; Salas E; Coupez R; Stockis A; Lu ZS
Epilepsy Res; 2007 Apr; 74(1):60-9. PubMed ID: 17270398
[TBL] [Abstract][Full Text] [Related]
8. Effects of amoxicillin/clavulanic acid on the pharmacokinetics of valproic acid.
Lee SY; Huh W; Jung JA; Yoo HM; Ko JW; Kim JR
Drug Des Devel Ther; 2015; 9():4559-63. PubMed ID: 26309401
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic study of levetiracetam in children.
Pellock JM; Glauser TA; Bebin EM; Fountain NB; Ritter FJ; Coupez RM; Shields WD
Epilepsia; 2001 Dec; 42(12):1574-9. PubMed ID: 11879369
[TBL] [Abstract][Full Text] [Related]
10. Single-dose intravenous administration of antiepileptic drugs induces rapid and reversible remodeling in the brain: Evidence from a voxel-based morphometry evaluation of valproate and levetiracetam in rhesus monkeys.
Tang Y; Yu X; Zhang X; Xia W; Wu X; Zou X; Li H; Huang X; Stefan H; Chen Q; Gong Q; Zhou D
Neuroscience; 2015 Sep; 303():595-603. PubMed ID: 26197226
[TBL] [Abstract][Full Text] [Related]
11. Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy.
Muñana KR; Nettifee-Osborne JA; Papich MG
J Vet Intern Med; 2015; 29(2):614-9. PubMed ID: 25711374
[TBL] [Abstract][Full Text] [Related]
12. Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage.
Mink S; Muroi C; Seule M; Bjeljac M; Keller E
Clin Neurol Neurosurg; 2011 Oct; 113(8):644-8. PubMed ID: 21703756
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of levetiracetam in Japanese and Western adults.
Pigeolet E; Jacqmin P; Sargentini-Maier ML; Stockis A
Clin Pharmacokinet; 2007; 46(6):503-12. PubMed ID: 17518509
[TBL] [Abstract][Full Text] [Related]
14. Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model.
Wojda E; Wlaz A; Patsalos PN; Luszczki JJ
Epilepsy Res; 2009 Oct; 86(2-3):163-74. PubMed ID: 19596559
[TBL] [Abstract][Full Text] [Related]
15. Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas.
Fay MA; Sheth RD; Gidal BE
Clin Ther; 2005 May; 27(5):594-8. PubMed ID: 15978308
[TBL] [Abstract][Full Text] [Related]
16. Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study.
Tinchon A; Oberndorfer S; Marosi C; Gleiss A; Geroldinger A; Sax C; Sherif C; Moser W; Grisold W
J Neurol; 2015 Jan; 262(1):179-86. PubMed ID: 25359262
[TBL] [Abstract][Full Text] [Related]
17. Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers.
Chen LC; Chou MH; Lin MF; Yang LL
J Clin Pharm Ther; 2000 Dec; 25(6):453-9. PubMed ID: 11123499
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
Chhun S; Jullien V; Rey E; Dulac O; Chiron C; Pons G
Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
[TBL] [Abstract][Full Text] [Related]
19. Comparison of reproductive effects of levetiracetam and valproate studied in prepubertal porcine ovarian follicular cells.
Taubøll E; Gregoraszczuk EL; Tworzydø A; Wójtowicz AK; Ropstad E
Epilepsia; 2006 Sep; 47(9):1580-3. PubMed ID: 16981877
[TBL] [Abstract][Full Text] [Related]
20. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin.
Ragueneau-Majlessi I; Levy RH; Meyerhoff C
Epilepsy Res; 2001 Nov; 47(1-2):55-63. PubMed ID: 11673021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
